Charmacy Pharmaceutical Co., Ltd.
Symbol: 2289.HK
HKSE
10.6
HKDDzisiejsza cena rynkowa
26.5108
Wskaźnik P/E
-0.6536
Wskaźnik PEG
1.14B
Kapitalizacja MRK
- 0.08%
Rentowność DIV
Charmacy Pharmaceutical Co., Ltd. (2289-HK) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2048.73 | 634.2 | 503.8 | 641.8 | |||||||||||
balance-sheet.row.short-term-investments | 33.27 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.net-receivables | 3455.49 | 965.4 | 865.3 | 731.3 | |||||||||||
balance-sheet.row.inventory | 2642.09 | 775.8 | 586.9 | 509.2 | |||||||||||
balance-sheet.row.other-current-assets | 1683.13 | 436.6 | 506.4 | 356 | |||||||||||
balance-sheet.row.total-current-assets | 9829.44 | 2812 | 2462.4 | 2238.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 1267.58 | 328.5 | 294.1 | 348.4 | |||||||||||
balance-sheet.row.goodwill | 24.1 | 6 | 6 | 6 | |||||||||||
balance-sheet.row.intangible-assets | 376.24 | 76.7 | 80.9 | 143 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 400.34 | 82.7 | 86.9 | 149.1 | |||||||||||
balance-sheet.row.long-term-investments | 1234.74 | 0 | 374.7 | 489.3 | |||||||||||
balance-sheet.row.tax-assets | 29.25 | 7.4 | 6.2 | 8.2 | |||||||||||
balance-sheet.row.other-non-current-assets | -1239.64 | 17 | -381 | -497.5 | |||||||||||
balance-sheet.row.total-non-current-assets | 1692.27 | 435.7 | 381 | 497.5 | |||||||||||
balance-sheet.row.other-assets | 71.28 | 0 | 22.6 | 27.4 | |||||||||||
balance-sheet.row.total-assets | 11593 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.account-payables | 3709.65 | 659.1 | 876.8 | 809.8 | |||||||||||
balance-sheet.row.short-term-debt | 5654.1 | 1531.1 | 1390 | 1512.6 | |||||||||||
balance-sheet.row.tax-payables | 296.21 | 56 | 94.2 | 44.6 | |||||||||||
balance-sheet.row.long-term-debt-total | 131.02 | 30.4 | 15.8 | 86.9 | |||||||||||
Deferred Revenue Non Current | -1.37 | -0.6 | 0 | 0.3 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.52 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 3492.36 | 2.5 | 1378.8 | 1349.2 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 132.52 | 31 | 15.8 | 86.9 | |||||||||||
balance-sheet.row.other-liabilities | 11.38 | 0 | 0 | 13.2 | |||||||||||
balance-sheet.row.capital-lease-obligations | 84.83 | 37 | 15.8 | 15.5 | |||||||||||
balance-sheet.row.total-liab | 9303.15 | 2649.8 | 2271.4 | 2259 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 432 | 108 | 108 | 108 | |||||||||||
balance-sheet.row.retained-earnings | 712.22 | 181.2 | 207.5 | 117.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 280.97 | 279 | 1 | 1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 864.66 | 29.7 | 278 | 278 | |||||||||||
balance-sheet.row.total-stockholders-equity | 2289.85 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 11593 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 2289.85 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 11593 | - | - | - | |||||||||||
Total Investments | 33.27 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.total-debt | 5796.4 | 1561.5 | 1405.8 | 1611.9 | |||||||||||
balance-sheet.row.net-debt | 3780.94 | 927.3 | 913.1 | 981.8 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 141.73 | 90.4 | 23.2 | 40.6 | ||||||||||
cash-flows.row.depreciation-and-amortization | 41.75 | 28.8 | 32 | 24.6 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | -404.55 | -300.2 | 20.9 | -227.9 | ||||||||||
cash-flows.row.account-receivables | -187.1 | -222.5 | -54.8 | -158 | ||||||||||
cash-flows.row.inventory | -217.45 | -77.7 | 75.8 | -69.8 | ||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-non-cash-items | 36.34 | 225 | -95.7 | 293.8 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -184.73 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -38.77 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | -2.9 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 160.41 | 80.4 | 0.6 | 0.1 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 121.65 | 71.8 | -24.4 | -54.8 | ||||||||||
cash-flows.row.debt-repayment | 0 | -1074.5 | -824.1 | -888.6 | ||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | -40.42 | -28.4 | -52.5 | -56.5 | ||||||||||
cash-flows.row.other-financing-activites | 52.15 | 911.7 | 951 | 942.5 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 11.73 | -191.2 | 74.4 | -2.7 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.05 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -51.31 | -75.4 | 30.5 | 73.6 | ||||||||||
cash-flows.row.cash-at-end-of-period | 332.42 | 68.9 | 144.2 | 113.8 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 383.73 | 144.2 | 113.8 | 40.1 | ||||||||||
cash-flows.row.operating-cash-flow | -184.73 | 44.1 | -19.5 | 131.1 | ||||||||||
cash-flows.row.capital-expenditure | -38.77 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.free-cash-flow | -223.5 | 35.5 | -44.6 | 79.1 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 8578.91 | 4403.6 | 4175.3 | 3793.6 | |||||||||||
income-statement-row.row.cost-of-revenue | 8017.56 | 4110.9 | 3906.7 | 3559.5 | |||||||||||
income-statement-row.row.gross-profit | 561.35 | 292.7 | 268.6 | 234.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 97.18 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 235.39 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.operating-expenses | 304.92 | 178 | 116.1 | 163.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 8322.48 | 4288.9 | 4022.8 | 3722.9 | |||||||||||
income-statement-row.row.interest-income | 66.96 | 4.3 | 30.5 | 37.7 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 235.39 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -12.61 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.total-operating-expenses | -12.61 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 53.79 | 26.5 | 25.7 | 29.1 | |||||||||||
income-statement-row.row.ebitda-caps | 255.88 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 202.09 | 66.2 | 93.5 | 74.4 | |||||||||||
income-statement-row.row.income-before-tax | 189.47 | 67.4 | 122.1 | 33 | |||||||||||
income-statement-row.row.income-tax-expense | 47.75 | 16.1 | 31.7 | 9.8 | |||||||||||
income-statement-row.row.net-income | 141.73 | 51.3 | 90.5 | 23.2 |
Często zadawane pytania
Ile wynosi Charmacy Pharmaceutical Co., Ltd. (2289.HK) aktywów ogółem?
Charmacy Pharmaceutical Co., Ltd. (2289.HK) całkowite aktywa to 3247655876.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 4403633477.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.066.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to -2.398.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.012.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.025.
Co to jest Charmacy Pharmaceutical Co., Ltd. (2289.HK) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi 51344725.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 1561459369.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 178011533.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 634197229.000.